



Innovating for  
affordable healthcare

# Shilpa Medicare Limited

**Manufacturers and Exporters of Bulk Drugs**

# 12-6-214/A1, Hyderabad Road,  
RAICHUR - 584 135. Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91-8532-238876

CIN No. L85110KA1987PLC008739

E-mail : info@vbshilpa.com Website : www.vbshilpa.com

Dated: 31 Jan, 2020

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India  
Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**MUMBAI-400 051**

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.**

**Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

\*\*\*\*\*

This is to inform you that the Company has received CDSCO -New Delhi Permission for manufacturing and marketing of Lenvatinib capsules 4mg and 10mg in India. Shilpa Medicare Limited is the first company to obtain Generic approval for Lenvatinib Capsules 4mg and 10mg in India.

Lenvatinib capsules 4mg and 10mg is a generic equivalent of reference product, Lenvima, used in the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer and for the first line treatment of patients with unresectable hepatocellular carcinoma.

According to IQVIA MAT Q2 2019 data, the Indian market for Lenvatinib capsules 4mg and 10mg is approximately US\$ 0.32 million.

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**

*V.V.K. Chaitanya*

**V V KRISHNA CHAITANYA  
COMPANY SECRETARY**

